Reversible Suppression of Menstruation with Antiprogestins
Abstract
The goal of this research was to utilize nonhuman primates to explore a safe, reversible method of menstrual suppression through progesterone antagonist therapy. During a normal menstrual cycle, progesterone (P) secreted in the luteal phase of the cycle primes the endometrium for menstruation. When P levels fall at the end of the cycle menstruation ensues. Progesterone antagonists (antiprogestins, PAs) are compounds that bind to the P receptor and block P action. Continuous blockade of P action during the menstrual cycle by PAs would prevent progestational priming of the endometrium and thus inhibit menstruation. Any unopposed effects of estrogen on the endometrium would also be blocked by another effect of PAs, the endometrial antiproliferative or so-called noncompetitive antiestrogenic effect. The mechanism underlying the "antiestrogenic effect" of PAs was also investigated and new insights were gained on the role of androgens in this effect. Our final report indicates that PA therapy is a reliable, reversible suppressor of menstruation, that the PA can be delivered both systemically, vaginally and through an intrauterine device, and that endometrial androgens may play a role in the endometrial antiproliferative effects of PAs. Once clinically tested and validated in women, PA therapy should provide the military woman with several new options for control of her menstrual periods.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA391359
Entities
People
- Robert M. Brenner